IL13 and ulcerative colitis: Among these cytokines, IL13 is most effective in patients with ulcerative colitis (UC) and fistulizing Crohn’s disease (CD), which makes anti-IL13 agents a promising therapeutic strategy for the management of inflammatory bowel disease (IBD) [66].